Peter F. Lenehan, Lisa A. Boardman, Douglas Riegert-Johnson, Giovanni De Petris, David W. Fry, Jeanne Ohrnberger, Eugene R. Heyman, Brigitte Gerard, Arpit A. Almal and William P. Worzel Generation and external validation of a tumor-derived 5-gene prognostic signature for recurrence of lymph node-negative, invasive colorectal carcinoma Cancer 118
Version of Record online: 17 MAY 2012 | DOI: 10.1002/cncr.27628
The first tumor gene-based prognostic assay (OncoDefender-CRC) for both stage I colorectal cancer and stage II colon cancer has been generated and externally validated. It outperforms standard clinicopathologic prognostic criteria and identifies those patients most likely to develop recurrent disease within 3 years after curative surgery and who, thus, are most likely to benefit from adjuvant treatment.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field